These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 1919622)

  • 1. Biochemical modulation: a modality that has come of therapeutic age.
    Allegra CJ
    J Clin Oncol; 1991 Oct; 9(10):1723-6. PubMed ID: 1919622
    [No Abstract]   [Full Text] [Related]  

  • 2. Biochemical modulation of 5-fluorouracil by PALA.
    O'Dwyer PJ
    Cancer Invest; 1990; 8(2):261-2. PubMed ID: 2400945
    [No Abstract]   [Full Text] [Related]  

  • 3. Phase I trial of PALA, methotrexate, fluorouracil, leucovorin, and uridine rescue in patients with advanced cancer. The use of uridine to decrease fluorouracil toxicity.
    Kemeny NE; Schneider A; Martin DS
    Cancer Invest; 1990; 8(2):263-4. PubMed ID: 2400946
    [No Abstract]   [Full Text] [Related]  

  • 4. How to optimize the effect of 5-fluorouracil modulated therapy in advanced colorectal cancer.
    Ragnhammar P; Blomgren H
    Med Oncol; 1995 Sep; 12(3):187-201. PubMed ID: 8852401
    [No Abstract]   [Full Text] [Related]  

  • 5. Clinical trials referral resource. Treatment of advanced colorectal cancer.
    Cheson BD
    Oncology (Williston Park); 1991 Apr; 5(4):61-2, 65-6, 68 passim. PubMed ID: 1831041
    [No Abstract]   [Full Text] [Related]  

  • 6. Chemotherapy of advanced cancer of the colon and rectum.
    Bruckner HW; Motwani BT
    Semin Oncol; 1991 Oct; 18(5):443-61. PubMed ID: 1925632
    [No Abstract]   [Full Text] [Related]  

  • 7. Cancer chemotherapy: past is prologue.
    Martin DS
    Mt Sinai J Med; 1985 Jun; 52(6):426-34. PubMed ID: 3875021
    [No Abstract]   [Full Text] [Related]  

  • 8. Biochemical modulation: application of laboratory models to the clinic.
    Leyland-Jones B; O'Dwyer PJ
    Cancer Treat Rep; 1986 Jan; 70(1):219-29. PubMed ID: 3510736
    [No Abstract]   [Full Text] [Related]  

  • 9. The pharmacologic modulation of 5-fluorouracil with folinic acid, methotrexate, trimetrexate, and n-phosphonacetyl-l-aspartic acid (PALA). Mechanisms of the interactions and clinical data.
    Machover D
    Bull Cancer; 1994 Dec; 81 Suppl 2():74s-77s. PubMed ID: 7727863
    [No Abstract]   [Full Text] [Related]  

  • 10. Metastatic colorectal cancer: advances in biochemical modulation and new drug development.
    Meropol NJ; Creaven PJ; Petrelli NJ
    Semin Oncol; 1995 Oct; 22(5):509-24. PubMed ID: 7570061
    [No Abstract]   [Full Text] [Related]  

  • 11. Sparfosate. A novel biomodulator of 5-fluorouracil.
    Koshland P; Maa L; Ignoffo R
    Cancer Pract; 1999; 7(4):212-6. PubMed ID: 10687588
    [No Abstract]   [Full Text] [Related]  

  • 12. Overview of N-(phosphonacetyl)-L-aspartate + fluorouracil in clinical trials.
    Martin DS; Kemeny NE
    Semin Oncol; 1992 Apr; 19(2 Suppl 3):228-33. PubMed ID: 1557654
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase II trial of biochemical modulation using N-phosphonacetyl-L-aspartate, high-dose methotrexate, high-dose 5-fluorouracil, and leucovorin in patients with adenocarcinoma of unknown primary site.
    Kelsen D; Martin DS; Colofiore J; Sawyer R; Coit D
    Cancer; 1992 Oct; 70(7):1988-92. PubMed ID: 1381991
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enhanced antitumor activity of an adriamycin + 5-fluorouracil combination when preceded by biochemical modulation.
    Stolfi RL; Colofiore JR; Nord LD; Martin DS
    Anticancer Drugs; 1996 Jan; 7(1):100-4. PubMed ID: 8742105
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sequential biochemical modulation of fluorouracil with folinic acid, N-phosphonacetyl-L-aspartic acid, and interferon alfa-2a in advanced colorectal cancer.
    Royce ME; McGarry W; Bready B; Dakhil SR; Belt RJ; Goodwin JW; Gray R; Hoff PM; Winn R; Pazdur R
    J Clin Oncol; 1999 Oct; 17(10):3276-82. PubMed ID: 10506630
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The dead end of 5-fluorouracil double modulation and promise of continuous infusion schedules in the treatment of metastatic colorectal cancer.
    Köhne CH; Wilke H; Schöffski P; Schmoll HJ
    J Infus Chemother; 1996; 6(4):206-10. PubMed ID: 9229317
    [No Abstract]   [Full Text] [Related]  

  • 17. 5-Ethynyluracil (776C85): modulation of 5-fluorouracil efficacy and therapeutic index in rats bearing advanced colorectal carcinoma.
    Cao S; Rustum YM; Spector T
    Cancer Res; 1994 Mar; 54(6):1507-10. PubMed ID: 8137256
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hepatotoxicity of fluorouracil with N-phosphonacetyl-L-aspartate.
    Stenram U
    Ann Intern Med; 1992 Jul; 117(1):90-1. PubMed ID: 1530700
    [No Abstract]   [Full Text] [Related]  

  • 19. Fluorouracil modulation in colorectal cancer: lack of improvement with N -phosphonoacetyl- l -aspartic acid or oral leucovorin or interferon, but enhanced therapeutic index with weekly 24-hour infusion schedule--an Eastern Cooperative Oncology Group/Cancer and Leukemia Group B Study.
    O'Dwyer PJ; Manola J; Valone FH; Ryan LM; Hines JD; Wadler S; Haller DG; Arbuck SG; Weiner LM; Mayer RJ; Benson AB
    J Clin Oncol; 2001 May; 19(9):2413-21. PubMed ID: 11331320
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of thymidine in biochemical modulation: a review.
    O'Dwyer PJ; King SA; Hoth DF; Leyland-Jones B
    Cancer Res; 1987 Aug; 47(15):3911-9. PubMed ID: 3300957
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.